GlassScriptPhysician profile
Stanley Pietrak
NPI 1396794939
$4,121.21
in general payments reported to CMS, 2019-2025
24 companies · $549 in 2025
The $549 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $723 · 2020: $60.98 · 2021: $445 · 2022: $1,023 · 2023: $525 · 2024: $795 · 2025: $549.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,869.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,869.04 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,113.43 | 2019-2025 | |
| Janssen Biotech, INC. | $641.14 | 2019-2025 | Tremfya, Stelara |
| Cook Medical LLC | $598.73 | 2019-2022 | |
| Pfizer INC. | $285.04 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $188.96 | 2019-2025 | Xifaxan, Trulance |
| Alfasigma USA, INC. | $161.60 | 2022 | |
| Boston Scientific Corporation | $158.92 | 2023 | Exalt Model D |
| Takeda Pharmaceuticals U.S.A., INC. | $152.43 | 2019-2025 | Entyvio, Eohilia |
| Madrigal Pharmaceuticals | $141.64 | 2024 | Rezdiffra, Resmetirom |
| Lilly USA, LLC | $119.06 | 2025 | Omvoh, Zepbound |
| Qol Medical, LLC | $103.94 | 2024-2025 | Sucraid, Sucraid |
| Celgene Corporation | $86.58 | 2022-2024 | Zeposia |
| Allergan, INC. | $52.26 | 2019-2020 | |
| Genzyme Corporation | $51.74 | 2023 | |
| Ardelyx, INC. | $49.90 | 2025 | Ibsrela |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $38.05 | 2023-2024 | Cyltezo |
| Braintree Laboratories, INC. | $35.72 | 2023 | Sutab |
| Aimmune Therapeutics, INC. | $24.70 | 2025 | Zenpep |
| Gilead Sciences, INC. | $24.51 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $22.37 | 2025 | Iqirvo |
| Merck Sharp & Dohme LLC | $20.05 | 2024 | Dificid |
| Intercept Pharmaceuticals, INC. | $17.51 | 2025 | |
| Cumberland Pharmaceuticals, INC. | $17.49 | 2025 | Kristalose |
| Teva Pharmaceuticals USA, INC. | $15.44 | 2024 | Simlandi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stanley Pietrak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.